<div id="readability-page-1"><div><p>As global markets continue to navigate geopolitical tensions and economic shifts, Asian equities are capturing investor attention with their potential for growth. In this environment, identifying stocks that may be trading below their fair value can offer opportunities for investors seeking to capitalize on market inefficiencies.</p><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3><table><tbody><tr><td><strong>Name</strong></td><td><strong>Current Price</strong></td><td><strong>Fair Value (Est)</strong></td><td><strong>Discount (Est)</strong></td></tr><tr><td>Zhongji Innolight (SZSE:300308)</td><td>CN¥585.76</td><td>CN¥1156.92</td><td>49.4%</td></tr><tr><td>Zhejiang Jiemei Electronic And Technology (SZSE:002859)</td><td>CN¥29.74</td><td>CN¥59.28</td><td>49.8%</td></tr><tr><td>TLB (KOSDAQ:A356860)</td><td>₩59100.00</td><td>₩116379.17</td><td>49.2%</td></tr><tr><td>Suning.com (SZSE:002024)</td><td>CN¥1.66</td><td>CN¥3.26</td><td>49%</td></tr><tr><td>PharmaResearch (KOSDAQ:A214450)</td><td>₩430000.00</td><td>₩851013.65</td><td>49.5%</td></tr><tr><td>PeptiDream (TSE:4587)</td><td>¥1753.00</td><td>¥3431.97</td><td>48.9%</td></tr><tr><td>HD Renewable Energy (TWSE:6873)</td><td>NT$104.50</td><td>NT$207.45</td><td>49.6%</td></tr><tr><td>Guoquan Food (Shanghai) (SEHK:2517)</td><td>HK$3.87</td><td>HK$7.64</td><td>49.4%</td></tr><tr><td>Andes Technology (TWSE:6533)</td><td>NT$241.00</td><td>NT$481.50</td><td>49.9%</td></tr><tr><td>Aidma Holdings (TSE:7373)</td><td>¥3210.00</td><td>¥6305.80</td><td>49.1%</td></tr></tbody></table><p>Click here to see the full list of 258 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p><p>We'll examine a selection from our screener results.</p><h2>Nanjing Vazyme Biotech (SHSE:688105)</h2><p><strong>Overview:</strong> Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics, with a market cap of CN¥8.87 billion.</p><p><strong>Operations:</strong> Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in the fields of life science, biomedicine, and in vitro diagnostics.</p><p><strong>Estimated Discount To Fair Value:</strong> 32.6%</p><p>Nanjing Vazyme Biotech is trading at CNY 22.3, significantly below its estimated fair value of CNY 33.06, indicating it is undervalued based on cash flows. Despite a recent decrease in net income to CNY 6.62 million for the nine months ended September 2025, earnings are projected to grow substantially by over 80% annually and surpass average market growth within three years. However, the dividend yield of 1.35% lacks coverage by earnings or free cash flow.</p><ul><li>Insights from our recent growth report point to a promising forecast for Nanjing Vazyme Biotech's business outlook.</li><li>Get an in-depth perspective on Nanjing Vazyme Biotech's balance sheet by reading our health report here.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>SHSE:688105 Discounted Cash Flow as at Jan 2026</figcaption></figure><h2>Anhui Ronds Science &amp; Technology (SHSE:688768)</h2><p><strong>Overview:</strong> Anhui Ronds Science &amp; Technology Incorporated Company offers solutions for machinery condition monitoring in the predictive maintenance sector in China, with a market cap of CN¥4.47 billion.</p><p><strong>Operations:</strong> Anhui Ronds Science &amp; Technology generates its revenue from providing solutions for machinery condition monitoring within the predictive maintenance industry in China.</p><p><strong>Estimated Discount To Fair Value:</strong> 45.1%</p><p>Anhui Ronds Science &amp; Technology is trading at CN¥50.81, significantly below its estimated fair value of CN¥92.54, highlighting its undervaluation based on cash flows. The company reported net income of CN¥26.9 million for the nine months ended September 2025, a substantial increase from the previous year. Earnings are forecast to grow significantly by over 30% annually, outpacing market averages, though dividend stability remains a concern with an unstable track record.</p><ul><li>The growth report we've compiled suggests that Anhui Ronds Science &amp; Technology's future prospects could be on the up.</li><li>Take a closer look at Anhui Ronds Science &amp; Technology's balance sheet health here in our report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>SHSE:688768 Discounted Cash Flow as at Jan 2026</figcaption></figure><h2>Baycurrent (TSE:6532)</h2><p><strong>Overview:</strong> Baycurrent, Inc. offers consulting services in Japan and has a market cap of approximately ¥1.04 billion.</p><p><strong>Operations:</strong> The company generates revenue from its Consulting Business segment, which amounts to ¥130.42 million.</p><p><strong>Estimated Discount To Fair Value:</strong> 34.5%</p><p>Baycurrent is trading at ¥6,828, notably below its estimated fair value of ¥10,424.18, underscoring its undervaluation based on cash flows. The company's earnings are projected to grow over 20% annually for the next three years, surpassing market averages. Despite slower revenue growth forecasts compared to earnings, Baycurrent's return on equity remains robust. Recent leadership changes and dividend increases may impact investor sentiment but don't alter the fundamental valuation appeal.</p><ul><li>Our earnings growth report unveils the potential for significant increases in Baycurrent's future results.</li><li>Click to explore a detailed breakdown of our findings in Baycurrent's balance sheet health report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>TSE:6532 Discounted Cash Flow as at Jan 2026</figcaption></figure><h2>Make It Happen</h2><ul><li>Embark on your investment journey to our 258 Undervalued Asian Stocks Based On Cash Flows selection here.</li><li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li><li>Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.</li></ul><h2>Interested In Other Possibilities?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.      It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

688105

688768

<p>Three Asian stocks identified as potentially undervalued include Anhui Ronds Science & Technology, trading at CN¥50.81 with a 45.1% discount to its fair value of CN¥92.54; Nanjing Vazyme Biotech, trading at CNY 22.3 with a 32.6% discount to its fair value of CNY 33.06; and Baycurrent, trading at ¥6,828 with a 34.5% discount to its fair value of ¥10,424.18. These companies show promising growth potential despite current market conditions, making them attractive for investors seeking undervalued opportunities.</p>

3 Asian Stocks That May Be Trading Below Fair Value By Up To 45.1%